

## Recommendations for Pediatric Use of Pneumococcal Conjugate Vaccine (PCV7) and Pneumococcal Polysaccharide Vaccine (23PS)

**TABLE A. For Children to two years of age**

Recommended Schedule of Doses for PCV7, Including Primary Series and Catch-Up Immunizations, in Previously Unvaccinated Children\*\*

Age at First Dose	Primary Series	Booster Dose†
2-6 mo	3 doses, 6-8 wk apart	1 dose at 12-15 mo of age
7-11 mo	2 doses, 6-8 wk apart	1 dose at 12-15 mo of age
12-23 mo	2 doses, 6-8 wk apart	

†Booster doses to be given at least 6 to 8 weeks after the final dose of the primary series.

### CDPHP Pediatric Preventive Health Guidelines Workgroup supports routine immunization for the following two groups of High Risk and Presumed High Risk Children:

I. Children at High Risk of Invasive Pneumococcal Infection (attack rate of invasive pneumococcal disease >150/100 000 cases/y)

- A. SCD, congenital or acquired asplenia, or splenic dysfunction
- B. Infection with HIV

II. Presumed high risk (attack rate not calculated)

- A. Congenital immune deficiency: some B- (humoral) or T-lymphocyte deficiencies, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), or phagocytic disorders (excluding chronic granulomatous disease)
- B. Chronic cardiac disease (particularly cyanotic congenital heart disease and cardiac failure)
- C. Chronic pulmonary disease (including asthma treated with high-dose oral corticosteroid therapy)
- D. Cerebrospinal fluid leaks
- E. Chronic renal insufficiency, including nephrotic syndrome
- F. Diseases associated with immunosuppressive therapy or radiation therapy (including malignant neoplasms, leukemias, lymphomas, and Hodgkin's disease) and solid organ transplantation\*
- G. Diabetes mellitus

**TABLE B**

Recommendations for Pneumococcal Immunization With PCV7 or 23PS Vaccine for Children at High Risk of Pneumococcal Disease, as listed above:

Age	Previous Doses	Recommendations
≤23 mo	None	Per Table A
24-59 mo	4 doses of PCV7	1 dose of 23PS vaccine at 24 mo, at least 6-8 wk after last dose of PCV7 1 dose of 23PS vaccine, 3-5 y after the first dose of 23PS vaccine
24-59 mo	1-3 doses of PCV7	1 dose of PCV7 1 dose of 23PS vaccine, 6-8 wk after the last dose of PCV7 1 dose of 23PS vaccine, 3-5 y after the first dose of 23PS vaccine
24-59 mo	1 dose of 23PS	2 doses of PCV7, 6-8 wk apart, beginning at least 6-8 wk after last dose of 23PS vaccine 1 dose of 23PS vaccine, 3-5 y after the first dose of 23PS vaccine
24-59 mo	None	2 doses of PCV7 6-8 wk apart 1 dose of 23PS vaccine, 6-8 wk after the last dose of PCV7 1 dose of 23PS vaccine, 3-5 y after the first dose of 23PS vaccine

\*Children with SCD, asplenia, HIV infection, and other high-risk factors.

\*\*These recommendations are adapted from the American Academy of Pediatrics, Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis. Physicians and other practitioners should consider individual member factors and use clinical judgement in applying these recommendations.